Amedeo's Top 20

Amedeo Smart

Independent Medical Education

17 January 2022

Multidisciplinary Journal Club

  1. McLornan DP, Pope JE, Gotlib J, Harrison CN, et al.
    Current and future status of JAK inhibitors.
    Lancet 2021;398:803-816.

  1. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, et al.
    Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    N Engl J Med 2022;386:24-34.

  2. .
    Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
    BMJ 2022;376:e068407.

  3. Fahrmann JF, Marsh T, Irajizad E, Patel N, et al.
    Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    J Clin Oncol 2022.

  4. Najidh S, Tensen CP, van der Sluijs-Gelling AJ, Teodosio C, et al.
    Improved Sezary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sezary syndrome.
    Blood 2021;138:2539-2554.

  1. Pal G, Mangone G, Hill EJ, Ouyang B, et al.
    Parkinson disease and STN-DBS: cognitive effects in GBA mutation carriers.
    Ann Neurol 2022.

  2. Khan SA, Zhao F, Goldstein LJ, Cella D, et al.
    Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
    J Clin Oncol 2022.

  3. .
    The freedom to grow.
    Cell 2021;184:5297-5300.

  4. Passaro A, Brahmer J, Antonia S, Mok T, et al.
    Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
    J Clin Oncol 2022.

  5. Reck M, Remon J, Hellmann MD.
    First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
    J Clin Oncol 2022.

  1. Edwards JK, Cole SR, Breger TL, Filiatreau LM, et al.
    Mortality for adults entering HIV care under universal early treatment compared to the general US population.
    Clin Infect Dis 2022.

  2. Berman NK, Honig S, Cronstein BN, Pillinger MH, et al.
    The effects of caffeine on bone mineral density and fracture risk.
    Osteoporos Int 2022.

  3. Bigaut K, Kremer L, Fabacher T, Ahle G, et al.
    Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    J Neurol 2022.

  4. Jukic A, Bakiri L, Wagner EF, Tilg H, et al.
    Calprotectin: from biomarker to biological function.
    Gut 2021;70:1978-1988.

  5. Sakuraba A, Luna A, Micic D.
    Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis.
    Gastroenterology 2022;162:88-108.e9.

  1. Chen SJ, Chen CC, Liao HY, Lin YT, et al.
    Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients.
    Neurology 2022.

  2. Stuck L, van Haaster AC, Kapata-Chanda P, Klinkenberg E, et al.
    How 'subclinical' is subclinical tuberculosis? An analysis of national prevalence survey data from Zambia.
    Clin Infect Dis 2022.

  3. Da Silva Soyombo NK, Rocha EL, Xavier LB, Oliveira RA, et al.
    Biomarkers for Differential Diagnosis Between Chronic Traumatic Encephalopathy and Alzheimer Disease: A Systematic Review.
    Neurology 2022;98:S15-S16.

  4. Gasbjerg KS, Hagi-Pedersen D, Lunn TH, Laursen CC, et al.
    Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial.
    BMJ 2022;376:e067325.

  5. Carrasquillo JA, Chen CC, Jha A, Ling A, et al.
    Imaging of Pheochromocytoma and Paraganglioma.
    J Nucl Med 2021;62:1033-1042.


more..

Privacy Policy